摘要
Objective:To compare the efficacy and safety of tacrolimus ointment and pimecrolimus cream in adult and pediatric patients with mild to very severe atopic dermatitis (AD). Methods:One thousand and sixty-five patients were randomized to treatment in 3 multicenter, randomized, investigator-blinded, 6-week studies. Results:Based on the Eczema Area Severity Index (EASI), tacrolimus ointment was more effective than pimecrolimus cream at the end of the study in adults (54.1%vs. 34.9%, respectively; P < .0001), in children with moderate/severe disease (67.2%vs. 56.4%, respectively; P=.04), in the combined analysis (52.8%vs. 39.1%, respectively; P < .0001), and at week 1 in children with mild disease (39.2%vs. 31.2%, respectively; P=.04). Tacrolimus was also more effective than pimecrolimus based on the Investigator Global AD Assessment (IGADA), improvement in percentage of total body surface area affected, and improvement in itch scores (P≤.05), with a faster onset of action. There was no significant difference in the incidence of adverse events (AEs), including applicationsitereactionsinthe2studiesinvolving650children. Adults treated with tacrolimus experienced a greater number of local application site reactions on day 1; both groups reported a similar incidence of application site reactions thereafter. More pimecrolimus-treated patients than tacrolimus-treated patients withdrew from the studies because of a lack of efficacy (P ≤.03) or adverse events (P=.002; pediatric mild). Conclusion:Tacrolimus ointment is more effective and has a faster onset of action than pimecrolimus cream in adults and children with AD; their safety profiles are similar.
Objective:To compare the efficacy and safety of tacrolimus ointment and pimecrolimus cream in adult and pediatric patients with mild to very severe atopic dermatitis (AD). Methods:One thousand and sixty-five patients were randomized to treatment in 3 multicenter, randomized, investigator-blinded, 6-week studies. Results:Based on the Eczema Area Severity Index (EASI), tacrolimus ointment was more effective than pimecrolimus cream at the end of the study in adults (54.1%vs. 34.9%, respectively; P < .0001), in children with moderate/severe disease (67.2%vs. 56.4%, respectively; P=.04), in the combined analysis (52.8%vs. 39.1%, respectively; P < .0001), and at week 1 in children with mild disease (39.2%vs. 31.2%, respectively; P=.04). Tacrolimus was also more effective than pimecrolimus based on the Investigator Global AD Assessment (IGADA), improvement in percentage of total body surface area affected, and improvement in itch scores (P≤.05), with a faster onset of action. There was no significant difference in the incidence of adverse events (AEs), including applicationsitereactionsinthe2studiesinvolving650children. Adults treated with tacrolimus experienced a greater number of local application site reactions on day 1; both groups reported a similar incidence of application site reactions thereafter. More pimecrolimus-treated patients than tacrolimus-treated patients withdrew from the studies because of a lack of efficacy (P ≤.03) or adverse events (P=.002; pediatric mild). Conclusion:Tacrolimus ointment is more effective and has a faster onset of action than pimecrolimus cream in adults and children with AD; their safety profiles are similar.
